# Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

> **NCT00365378** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2409 (actual)

## Conditions studied

- HPV 16 Infection

## Interventions

- **BIOLOGICAL:** Comparator: HPV 16 L1 Vaccine
- **BIOLOGICAL:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00365378
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2004-03
- **Final completion:** 2009-07
- **Target enrollment:** 2409 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365378, "Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00365378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*